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This phase II study was conducted to determine the efficacy and toxicity of a gemcitabine (GEM) and oxaliplatin (OX) chemotherapy
protocol in patients with unresectable biliary tract cancer (BTC). Patients were treated with GEM 1000mgm
 2 (30min infusion) on
days 1, 8, 15, and OX 100mgm
 2 (2h infusion) on days 1 and 15 (gemcitabine and oxaliplatin (GEMOX-3 protocol), repeated every
28 days. The data were collected according to the Simon 2-stage design for a single centre phase II study (a¼0.05; b¼0.2). Primary
end point was response rate; secondary end points were time-to-progression (TTP), median survival, and safety profile. Thirty-one
patients were enrolled in the study between July 2002 and April 2005. Therapeutic responses were as follows: partial response in
eight patients (26%, 95% confidence interval (CI) 14–44), stable disease in 14 patients (45%, 95%CI 29–62), resulting in a disease
control rate of 71%. Nine patients (29%, 95%CI 16–47) had progressive disease. Median TTP was 6.5 months. Median overall
survival was 11 months. Common Toxicity Criteria (CTC) Grade 3–4 toxicities were transient thrombocytopenia (23%), peripheral
sensory neuropathy (19%), leucopenia (16%), and anaemia (10%). In conclusion the GEMOX-3 protocol is active and well tolerated
in patients with advanced BTC. It can be applied in an outpatient setting with three visits per month only.
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Biliary tract cancer (BTC) is a heterogeneous tumour entity with a
dismal prognosis. Incidence and mortality rates of intrahepatic
cholangiocarcinomas are rising, whereas gall bladder and extra-
hepatic cholangiocarcinoma incidences are slightly declining
(Patel, 2001, 2002; Khan et al, 2002). At present, surgery is the
only curative treatment option for BTC. However, less than 25% of
patients are resectable at presentation with high relapse rates after
surgery (Oertli et al, 1993; de Groen et al, 1999). The 5-year
survival rates after resection for intrahepatic cholangiocarcinomas
vary from 8–47% (Nakeeb et al, 2002).
A benefit over no therapy or best supportive care has been
demonstrated for palliative treatment options with either surgical
or endoscopic biliary drainage, and/or chemotherapy (Farley et al,
1995; Chang et al, 1998). However, no standard chemotherapy
exists, owing to the rarity, and heterogeneity of the disease.
In recent phase-II trials, gemcitabine (GEM), a pyrimidine
analogue, has been shown to be an active single agent therapy in
BTC. For this drug objective response rates (RR) in a range from
8 to 60% have been reported (Raderer et al, 1999; Valencak et al,
1999; Gallardo et al, 2001; Gebbia et al, 2001; Kubicka et al, 2001;
Penz et al, 2001). In addition, various combination therapies have
been investigated in the setting of phase II studies with RRs
between 9.5 and 53% (Gebbia et al, 2001; Patt et al, 2001; Doval
et al, 2002; Kuhn et al, 2002; Nehls et al, 2002; Taieb et al, 2002;
Kornek et al, 2004; Patt et al, 2004; Alberts et al, 2005; Ducreux
et al, 2005). Overall, most favourable RRs in BTC were reached
with protocols that combine cisplatin (CDDP) with 5-fluorouracil
or GEM (Doval et al, 2002; Taieb et al, 2002; Ducreux et al, 2005).
Another combination regimen, which replaces CDDP by the
third generation platinum analogue oxaliplatin (OX) could help to
reduce the emetic and potential renal toxicity of CDDP without
loss of treatment efficacy (Extra et al, 1998). A French study used
the combination of GEM and OX in pancreatic cancer with
promising results. Because of some similarities in tumour biology
and response to chemotherapeutic agents between pancreatic and
BTC we reasoned that gemcitabine and oxaliplatin (GEMOX)
might be active in BTC as well. Therefore, the rationale for our
study was to design a patient friendly protocol, with two in other
cancers well tolerated and active substances. In the study by
Louvet et al (2002) the two substances were given on 2 consecutive
days with relatively long infusion times (fixed dose rate) for GEM.
In contrast, we chose to apply GEM as an infusion over 30min
followed by OX as a 2h infusion on the same day in an outpatient
setting.
PATIENTS AND METHODS
Patients
Patients included in the study were required to meet the following
criteria: 18–75 years old, written informed consent, histologically
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sor cytologically confirmed and non-resectable or metastatic BTC,
one or more bidimensionally measurable lesions on computed
tomography (CT) or magnetic resonance imaging (MRI), Karnofsky
Score X70%, leucocyte X3 10
9l
 1, platelets X100 10
9l
 1,
serum creatinine o2mgdl
 1, and bilirubin o3mgdl
 1, a life
expectancy over 3 months, absence of cholangitis or carcinoma of
the ampulla of Vater. Primary gastrointestinal cancers other than
BTC were excluded by upper endoscopy, colonoscopy, and
multislice CT scan. Women were either postmenopausal or were
using adequate contraception with a negative pregnancy test at
study entry. Patients were excluded in case of preexisting
peripheral neuropathy National Cancer Institute-Common Toxi-
city Criteria (NCI CTC)4grade 1, use of major surgery or
chemotherapy within 1 month, or radiotherapy within 12 months
of study entry. Patients were allowed to have received prior
chemotherapy (not including GEM or OX) for advanced disease or
in the adjuvant setting. The baseline characteristics at study entry
are given in Table 1. Patients with severe cardiovascular or
pulmonary disease (NYHA III-IV, global respiratory insufficiency),
symptomatic cerebral metastases, incompatibility with or allergy
to platinol derivates, pregnancy, or lactation, serious infection,
additional malignancies other than completely excised in situ
carcinoma of the cervix or non-melanomatous skin cancer, and
current alcohol or drug addiction were also excluded from the
study. The study was carried out according to the Declaration of
Helsinki Principles, the Good Clinical Practice criteria and was
approved by the local ethics committee. The study was performed
without sponsoring.
Treatment plan
All patients received the treatment protocol GEMOX-3 on an
outpatient basis as follows: first GEM 1000mgm
 2 as infusion over
30min on days 1, 8, and 15, thereafter OX 100mgm
 2 over 2h on
days 1 and 15. Treatment was repeated every 28 days. NCI CTC
version 2.0 was used for toxicity assessment. In addition a separate
neurotoxicity scale for the assesment of OX-induced sensory
neuropathy was used (Extra et al, 1998). Clinical examination
including measurement of sensory neuropathy, blood count, and
liver function tests were performed with each visit. In case of
specific cumulative peripheral sensory neuropathy NCI
CTC4grade 1 persisting over 7 days, the dose of OX was reduced
to 75mgm
 2. Oxaliplatin was stopped in case of grade 3 or 4
peripheral sensory neuropathy. Treatment was subsequently
continued according to the same schedule, but with GEM alone.
With leucocytes o3.0 10
9l
 1 or platelet count o100 10
9l
 1
treatment was interrupted for 7 days. These criteria were applied to
any day of treatment administration. If recovery occurred within
the 7 days, treatment was continued without dose reduction,
otherwise the dosages of GEM and OX were reduced to 75%. Doses
omitted were given within the two subsequent weeks. After
treatment discontinuation for more than 3 weeks the patients
went off study. Treatment was continued until disease progression,
unacceptable toxicity despite dose modification or patient with-
drawal.
Treatment evaluation and statistics
The data were collected according to Simon’s optimal two-stage
design for a single centre study (Simon, 1989). According to this
design, an additional 19 patients were to be enrolled in case of a
minimum RR of 10% in the first 10 patients. Thus, the planned
minimum sample size was 29. In case of more than three responses
in the total of 29 patients (RR of at least 10%), the regimen was
considered active with a¼0.05; b¼0.2. All enrolled patients were
included in the intention-to-treat analysis.
The primary end point was tumour response according the
response evaluation criteria in solid tumours guidelines (Therasse
et al, 2000). The response was specified in percent with 95%-CI
calculated by the modified Wald method (Agresti, 1998).
Secondary end points were time-to-progression (TTP), overall
survival (OS), and toxicity. Time-to-progression was determined
from the first day of treatment until tumour progression assessed
by CT scan or MRI. OS was determined from first day of treatment
until death. Time-to-progression and OS data were analysed by
means of the Kaplan–Meier method.
RESULTS
Patient characteristics
The median duration of follow up was 13 months. The cutoff date
for data analysis was 21 December 2005. Thirty-one consecutive
patients at the Department of Medicine of the University of
Freiburg, Germany, were enrolled from July 2002 to April 2005.
Demographics and other baseline characteristics are summarised
in Table 1. The study included 13 men and 18 women with a
median age of 63 years (38–75). The primary cancer site has been:
Table 1 Baseline characteristics of 31 patients with BTC
Characteristic N (%)
Sex
Male 13 42
Female 18 58
Age, years
Median 63
Range 38–75
Karnofsky score
70 1 3
80 4 13
90 6 19
100 20 65
Primary cancer site
Gallbladder 10 32
Intrahepatic bile ducts 14 45
Extrahepatic 7 23
Disease at presentation
Locally advanced 3 10
Metastatic 28 90
Metastatic sites
Liver 14 45
Lung 6 19
Lymph nodes 19 61
Prior therapy
None 17 55
Surgery 7 23
Endoscopic biliary stenting 6 19
Radiochemotherapy and stent 1 3
Chemotherapy 0 0
Presenting symptom
Pain 16 52
Jaundice 5 16
Weight loss 4 13
None 2 6
Fever 2 6
Fatigue 2 6
Total 20 65
Endoscopic biliary stenting during chemotherapy 3 10
BTC, biliary tract cancer.
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s14 (45%) intrahepatic bile ducts, 10 (32%) gallbladder, and 7 (23%)
extrahepatic bile ducts. The baseline characteristics are similar to
other phase II studies reported. Ampullary carcinomas were
excluded.
Safety and response
A total of 140 cycles of chemotherapy (420 treatment days) were
delivered during the study. The median number of cycles was 4
(range 0.66–10). Three patients did not complete the first two
cycles and were considered as progressive disease. One patient
died of duodenal perforation owing to tumour infiltration without
having completed the first cycle (received d1 and d8 only). In
another two patients, chemotherapy was stopped after 1.66 cycles
because of malignant biliary obstruction with consecutive devel-
opment of an intrahepatic abscess and a cholangitis, respectively.
Despite the absence of neutropenia, the immediate start of an
appropriate antibiotic treatment, and adequate biliary drainage,
both patients subsequently died of cholangiosepsis. Deaths in both
patients had been attributed to tumour progression, rather than
treatment related, although the latter could not completely be ruled
out. All 31 patients were assessable for toxicity. Treatment delays
of any reason were necessary in 27 out of 31 patients (87%). In 13
(42%) patients dose reductions had to be performed. In seven
patients (23%), the dose of GEM and OX had to be reduced owing
to bone marrow toxicity. In another six patients (19%), OX had to
be reduced and later discontinued owing to peripheral sensory
neuropathy. Sixty-six percent of treatment delays were caused
by bone marrow toxicity, especially thrombocytopenia below
100 10
9l
 1 (n¼69/54%). Another major reason for delay of
treatment were infections (9%), with febrile neutropenia in two
patients. Toxicities according to NCI CTC are summarised in
Table 2.
Despite these delays and dose reductions, eight patients (26,
95% CI 14–44%) had a partial response and 14 (45, 95% CI
29–62%) had stable disease. Thus, tumour control was achieved in
22 patients (71%). Median TTP was 6.4 month, whereas median OS
was 11.0 month. Tumour or response re-evaluation was performed
every other cycle by the same radiologic imaging (CT or MRI).
Patients needed to have stable disease for a minimum of 8 weeks to
be considered ‘disease control’.
Results are summarised in Table 3. Apart from the two patients
mentioned above, there were no treatment-related deaths.
DISCUSSION
Unresectable BTC is associated with a poor prognosis and
treatment options are limited. As palliative therapeutic approach
in patients with unresectable BTC we assessed the combination
chemotherapy of GEMOX-3. Our data demonstrate that in
advanced BTC the GEMOX-3 protocol shows good antitumour
activity and tolerable toxicity with 3 treatment days per month and
administration in an outpatient setting.
In palliative intention, novel combination chemotherapies are
being tested in order to increase RRs and survival without
additional toxicity. Although the combination of GEM and CDDP
showed favourable RRs (RR 36.6%), the regimen was associated
with a high frequency of grade 3 and 4 toxicities (Doval et al,
2004). At the start of the present study, two phase II trials have
been published which analysed combinations with the new
platinum component OX: GEM (fixed dose rate)/OX (RR 35.5%,
PFS 5.7 months, median OS 15.4 months) (Andre et al, 2004), and
capecitabine/OX (RR 26.6%, TTP NR, median OS NR) (Glover
et al, 2005). Other combinations, for example, capecitabine/GEM,
showed similar outcomes (RR 31%, PFS 7 months, OS 14 months)
(Knox et al, 2005) The results of our study (RR 26%, TTP 6.4, OS
11.0) now underscore that GEMOX is an active combination
chemotherapy with acceptable toxicity. The differences to the
study of Andre et al (2004), might be explained by the inclusion of
two groups of patients with different eligibility criteria in the
French study (higher/lower bilirubin cutoff, better/worse perfor-
mance status, previous chemotherapy). Although the group with
stricter restrictions reached a RR of 35.5% and a superior OS of
15.4 months, the other group showed a RR of 22% and an inferior
OS of 7.6 months. Longer infusion times of GEM (100min vs
30min) and the application of OX on a second day by Andre et al
(2004) might also have influenced the outcome. In general,
considering the short OS of patients with advanced BTC inpatient
chemotherapy protocols should be minimised.
Thrombocytopenia was the most frequent toxicity in our study,
but had no major clinical impact. The frequent treatment delays
(54%) might be explained by the high thrombocyte cutoff level of
100 10
9l
 1 chosen in the study and the cumulative toxicity of
GEM and OX at the doses used. Another 9% of treatment delays
were caused by infections of any kind, most frequently owing to
cholangitis and occlusion of biliary stents in patients with
Table 2 Grade 3–4 NCI CTC toxicities (n¼31) worst toxicity (all
cycles) per patient
Grade 3–4 toxicity N (%)
Leucocytopenia (grade 3) 5 16
Febrile neutropenia 2 7
Thrombocytopenia 7 23
Anaemia (grade 3) 3 10
Vomiting 0 0
Diarrhoea 0 0
Peripheral sensory neuropathy 6 19
Mucositis 0 0
NCI CTC, National Cancer Institute Common Toxicity Criteria.
Table 3 Treatment efficacy (n¼31)
Overall Intrahepatic Gallbladder Extrahepatic
Treatment response N % (95%-CI) N % N % N %
31 100 14 100 10 100 7 100
Complete response 0 0 0 0 0 0 0 0
Partial response 8 26 (14–44) 1 7 4 40 3 42
Stable disease 14 45 (29–62) 9 64 3 30 2 29
Progressive disease 9 29 (16–47) 4 29 3 30 2 29
Median TTP (months) 6.4 6.2 6.0 7.3
Median OS (months) 11.0 8.4 11.1 13.3
CI, confidence interval; OS, overall survival; TTP, time-to-progression.
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sextrahepatic and perihilar tumours. Despite this fact, patients with
intraductal growth type BTC, tended to have a better OS than
patients with mass forming type BTC (OS 13.3 vs 8.4).
With respect to neurotoxicity there was a clear relation between
cumulative OX dose and delayed sensory neuropathy, as described
in the literature (Extra et al, 1998; de Gramont et al, 2000). After
therapy discontinuation, however, there was a fast improvement of
treatment-related symptoms.
The important limitation of our study is its single centre phase II
design. Owing to the limited number of patients, it was not
possible to perform a randomised study comparing GEMOX to a
single agent. However, a disease control470% of patients suggests
that patients with unresectable BTC benefit from the combination
chemotherapy.
Some authors report an inferior RR in mass forming BTC (Nehls
et al, 2003; Andre et al, 2004), whereas others document a more
aggressive biology of gallbladder cancer (Doval et al, 2004, Knox
et al, 2005). Despite the data are limited by the low number of
patients it should be noted that patients with gallbladder cancer
and extrahepatic BTC showed a considerably better RR (40 and
42%) than patients with intrahepatic BTC (RR 7%). This
interesting observation should be verified in a larger trial that
allows for a differentiated subgroup analysis.
Furthermore, despite extensive diagnostic efforts it cannot be
ruled out that also patients with a cancer of unknown primary site
were included and lead to a bias in the data. More precise
molecular profile of the three BTC growth types will be necessary
to better distinguish BTC from other solid tumours.
In summary, GEMOX-3 is efficacious and can be safely given on
an outpatient basis as a palliative chemotherapy of advanced BTC.
These promising RRs now need to be verified in controlled phase
III trials, as they are currently ongoing.
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